Medicare AdvantagePrior AuthMedium impact
MA08.085j, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·MA · Oncology, Pharmacy·Pharmacy
Effective date
Aug 25, 2025
We identified it
Jun 19, 2026
Summary
This policy establishes medical necessity criteria for Rylaze® (Asparaginase Erwinia Chrysanthemi recombinant-rywn), a specialty pharmaceutical used in acute lymphoblastic leukemia treatment. The billing team must implement prior authorization requirements and ensure claims include proper medical necessity documentation to comply with this new MA plan coverage policy.
Action Required
By August 25, 2025: Billing team must implement prior authorization process for J9210 (Asparaginase Erwinia Chrysanthemi recombinant-rywn/Rylaze) on all Medicare Advantage claims. Update billing software to require medical necessity documentation before claim submission. Coordinate with oncology providers to ensure prescriptions include appropriate clinical documentation supporting leukemia diagnosis and medical necessity. Add this drug to the pharmacy prior auth checklist. Claims submitted without prior authorization or missing medical necessity criteria will be denied by the plan.